| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/25/2004 | US20040058904 Antiinflammatory agents; autoimmune disease |
| 03/25/2004 | US20040058903 Anticholesterol agents; cardiovascular disorders |
| 03/25/2004 | US20040058892 Antidiabetic agents |
| 03/25/2004 | US20040058855 Use of materials having zinc ionophoric behavior |
| 03/25/2004 | US20040058854 Synergistc therapy; bioavailability |
| 03/25/2004 | US20040058853 Multivalent neuraminidase inhibitor conjugates |
| 03/25/2004 | US20040058850 Using caspase inhibitor; antiinflammatory agents |
| 03/25/2004 | US20040058443 Manipulation of non-terminally differentiated cells using the Notch pathway |
| 03/25/2004 | US20040058367 Comprises interleukin 1b converting enzyme inhibitor for diagnosis, prevention and treatment of viral, nervous system, ischemic and graft-versus-host diseases |
| 03/25/2004 | US20040058366 Comprises DNA coding brain-muscle-arnt-like protein 2 (BMAL2) for diagnosis and treatment of circadian rythm disorders |
| 03/25/2004 | US20040058353 Comprises nucleotide sequences coding transport proteins for diagnosis and treatment of pain, psychotic, eating and nervous system disorders |
| 03/25/2004 | US20040058024 Comprises polyunsaturated fatty acid-containing composition extracted from Echium plants, with antilipemic agents, antioxidants, and antidiabetic agents, for formulation as dietary supplement |
| 03/25/2004 | US20040058022 Method for producing fat and /or solids from beans and compositions containing polyphenols |
| 03/25/2004 | US20040058021 Which suppresses I-kappa-B-alpha phosphorylation through inhibition kinase activity and downregulating NF-kappa-B; antiproliferative agents |
| 03/25/2004 | US20040058001 For controlled release; drug delivery |
| 03/25/2004 | US20040057990 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 03/25/2004 | US20040057964 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| 03/25/2004 | US20040057960 Activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells, using fusion proteins comprising HCV, NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins; immunogens |
| 03/25/2004 | US20040057953 Modified peptides as therapeutic agents |
| 03/25/2004 | US20040057929 Administering viruses selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus to mammal having Ras-activated pathway to result in lysis of proliferating cells |
| 03/25/2004 | US20040057925 Methods of enhancing bioactivity of chemokines |
| 03/25/2004 | US20040056240 Adhesive |
| 03/25/2004 | DE10262005A1 Foodstuff or pharmaceutical compositions containing hydrogenated condensed palatinose, useful e.g. as sweetener or soluble dietary fiber source and/or for combating intestinal inflammation or cancer |
| 03/25/2004 | DE10242062A1 New hydrogenated condensed palatinose products, useful in food, feed or medicament compositions, e.g. for combating diabetes or cancer, obtained by catalytic hydrogenation of condensed palatinose solution |
| 03/25/2004 | CA2502583A1 Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| 03/25/2004 | CA2498757A1 Proline ester and preparation containing the same for percutaneous administration |
| 03/25/2004 | CA2498723A1 Design of chemokine analogs for the treatment of human diseases |
| 03/25/2004 | CA2498269A1 Substituted aminoethers for the treatment of alzheimer's disease |
| 03/25/2004 | CA2497804A1 Human anti-human mcp-1 antibody and fragment of said antibody |
| 03/25/2004 | CA2497801A1 Paks as modifiers of the chk pathway and methods of use |
| 03/25/2004 | CA2497793A1 Flj20647s as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497790A1 Rors as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497571A1 Hydantoin derivatives and their use as tace inhibitors |
| 03/25/2004 | CA2497067A1 Amino-propanol derivatives |
| 03/25/2004 | CA2494274A1 Method and composition for regulating the activity of regulatory t cells |
| 03/24/2004 | EP1400576A1 Adhesive |
| 03/24/2004 | EP1400529A1 Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| 03/24/2004 | EP1400522A1 New compounds for treating impotence |
| 03/24/2004 | EP1400521A1 Piperazine compounds |
| 03/24/2004 | EP1400520A1 Crystal of 6- 4-(4-pyridylamino)phenyl]-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate |
| 03/24/2004 | EP1400519A1 Respiratory syncytial virus replication inhibitors |
| 03/24/2004 | EP1400518A1 Heterocyclic compound derivatives and medicines |
| 03/24/2004 | EP1400515A1 Cyclic diamine compound having five-membered cyclic group |
| 03/24/2004 | EP1400513A1 Unsymmetrical cyclic diamine compound |
| 03/24/2004 | EP1400510A1 Cyclic diamine compounds having fused-ring groups |
| 03/24/2004 | EP1400241A1 Fused cyclic compounds and medicinal use thereof |
| 03/24/2004 | EP1399739A2 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 03/24/2004 | EP1399578A2 Adsls as modifiers of the p53 pathway and methods of use |
| 03/24/2004 | EP1399574A2 Improved vectors for gene therapy |
| 03/24/2004 | EP1399570A2 Peptides for use as translocation factors |
| 03/24/2004 | EP1399565A2 Mitogenic oxygenase regulators |
| 03/24/2004 | EP1399552A2 G-protein coupled receptor proteins (gpcr) and nucleic acids encoding same |
| 03/24/2004 | EP1399548A2 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 03/24/2004 | EP1399479A2 Cation conducting gaba a receptors and their use |
| 03/24/2004 | EP1399469A2 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 03/24/2004 | EP1399468A1 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| 03/24/2004 | EP1399462A1 Combined approach to treatment of cancer using a c-myc antisense oligomer |
| 03/24/2004 | EP1399449A1 Carbohydrate derivatives |
| 03/24/2004 | EP1399448A1 Imidazo 1,5-a] pyrimido 5,4-d] benzazepine derivatives as gaba a receptor modulators |
| 03/24/2004 | EP1399446A1 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
| 03/24/2004 | EP1399442A1 Cak inhibitors and uses thereof |
| 03/24/2004 | EP1399440A1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 03/24/2004 | EP1399439A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 03/24/2004 | EP1399438A1 Novel heteroaryl derivatives, their preparation and use |
| 03/24/2004 | EP1399434A1 Novel indole derivatives |
| 03/24/2004 | EP1399432A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 03/24/2004 | EP1399431A2 Novel nitriles useful as reversible inhibitors of cysteine proteases |
| 03/24/2004 | EP1399428A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| 03/24/2004 | EP1399422A2 Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl] -1-hydroxybutyl] -a,a-dimethylbenzene acetic acid and its hydrochloride |
| 03/24/2004 | EP1399420A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 03/24/2004 | EP1399406A2 Novel estrogen receptor ligands and methods i |
| 03/24/2004 | EP1399221A1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand) |
| 03/24/2004 | EP1399190A1 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| 03/24/2004 | EP1399187A2 Uses of monoclonal antibody 8h9 |
| 03/24/2004 | EP1399179A2 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 03/24/2004 | EP1399177A1 Bmp binding proteins for use in bone or cartilage regeneration |
| 03/24/2004 | EP1399175A2 Therapeutic use of rank antagonists |
| 03/24/2004 | EP1399171A1 Medicinal herbal compounds for the prevention and treatment of diabetes |
| 03/24/2004 | EP1399166A1 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA |
| 03/24/2004 | EP1399162A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 03/24/2004 | EP1399161A2 Sustained-release analgesic compounds |
| 03/24/2004 | EP1399160A2 Nr2b receptor antagonists for the treatment or prevention of migraines |
| 03/24/2004 | EP1399157A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 03/24/2004 | EP1399156A2 Alkylidene pirazolidinedione derivatives and their use for treating diabetes and obesity |
| 03/24/2004 | EP1399155A2 Small molecules useful in the treatment of inflammatory disease |
| 03/24/2004 | EP1399154A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 03/24/2004 | EP1399153A2 Pharmaceutical composition comprising a drug and a fatty acid or salt thereof |
| 03/24/2004 | EP1399152A1 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 03/24/2004 | EP1399151A2 A method for treating inflammatory diseases by administering a ppar-delta agonist |
| 03/24/2004 | EP1399149A2 Taxane prodrugs |
| 03/24/2004 | EP1399147A2 Therapeutic delivery of carbon monoxide |
| 03/24/2004 | EP1399146A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/24/2004 | EP1399144A1 Carbamate compounds for use in preventing or treating anxiety disorders |
| 03/24/2004 | EP1399137A1 Sulfonamides |
| 03/24/2004 | EP1399119A2 Oral compositions and use thereof |
| 03/24/2004 | EP1399113A1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 03/24/2004 | EP1399023A2 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 03/24/2004 | EP1399021A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
| 03/24/2004 | EP1349558A4 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 03/24/2004 | EP1303517B1 Indoloquinazolinones |